Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
ContributorsDodel, Richard; Rominger, Axel; Bartenstein, Peter; Barkhof, Frederik; Blennow, Kaj; Förster, Stefan; Winter, Yaroslav; Bach, Jan-Philipp; Popp, Julius; Alferink, Judith; Wiltfang, Jens; Buerger, Katharina; Otto, Markus; Antuono, Piero; Jacoby, Michael; Richter, Ralph; Stevens, James; Melamed, Isaac; Goldstein, Jerome; Haag, Stefan; Wietek, Stefan; Farlow, Martin; Jessen, Frank
Published inThe Lancet Neurology, vol. 12, no. 3, p. 233-243
Publication date2013
Abstract
Keywords
- Aged
- Aged, 80 and over
- Alzheimer Disease/diagnosis/drug therapy/immunology
- Amyloid beta-Peptides/blood
- Area Under Curve
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Immunoglobulins, Intravenous/administration & dosage/adverse effects/blood
- Male
- Middle Aged
- Placebos
- Severity of Illness Index
Affiliation entities Not a UNIGE publication
Citation (ISO format)
DODEL, Richard et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. In: The Lancet Neurology, 2013, vol. 12, n° 3, p. 233–243. doi: 10.1016/S1474-4422(13)70014-0
Main files (1)
Article (Published version)
Identifiers
- PID : unige:106704
- DOI : 10.1016/S1474-4422(13)70014-0
- PMID : 23375965
Journal ISSN1474-4422
